ArticleInfection and drug resistance2020
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Pooled it
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Epidemiology and Azole Resistance of Clinical Isolates ofInfection and drug resistance · 2024Article
- The Molecular Identification and Antifungal Susceptibility of Clinical Isolates ofMicroorganisms · 2023Article
- Diagnostic Laboratory Features and Performance of anMicrobiology spectrum · 2023Article
- Epidemiology of Clinically SignificantInfection and drug resistance · 2023Article
- Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2022Article
- Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.Frontiers in public health · 2022Article
- A 20-Year Antifungal Susceptibility Surveillance (From 1999 to 2019) forFrontiers in microbiology · 2021Article
- Distribution ofTherapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate species diversity and prevalence of antifungal resistance among clinical isolates of PATIENTS AND
methodsIn this study, the
resultsThe most common
conclusionThe results of our study revealed a diversity of species in the lower respiratory tract of inpatients in Shanghai and approximately 9% of our isolates were resistant to at least one of the triazole antifungals. Formulation of local treatment strategies to combat emerging azole resistance and species diversity in clinically relevant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.